A panel of federal judges is considering Louisiana's assertion that mifepristone, a key drug in the most common abortion method in the U.S., should not be dispensed anywhere but a medical facility.

The 5th Circuit Court of Appeal in Louisiana will hear arguments on Wednesday in a case that could decide future telehealth access to mifepristone.

The 5th Circuit will hear Louisiana’s challenge to Biden-era abortion by mail rules as the FDA conducts a new mifepristone safety review.